Signal peptide mRNA for improving expression level of secretory protein and mRNA engineering method and application thereof
Through mRNA engineering and the use of lipid nanoparticle technology, the problem of low secreted protein expression level is solved, efficient secretion in cells and mice is achieved, suitable for the treatment of various diseases, and provides a kind of Stable and controllable protein replacement therapy.
Patent Information
- Application Number
- CN202411174918.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art is difficult to effectively improve the expression level of secreted proteins through mRNA engineering technology, especially in therapeutic mRNA drugs. The secretion efficiency of proteins is low and difficult to maintain high levels in the circulatory system, resulting in poor therapeutic effects.
The signal peptide sequence is engineered by mRNA, replacing the nucleic acid sequence of the original signal peptide, and optimizing the mRNA sequence encoding the secreted protein to improve the expression level of the secreted protein. The modified mRNA is introduced into the eukaryotic host using specific nucleic acid molecules and delivery vectors. In cells or host animals, lipid nanoparticles technology is used to improve protein secretion efficiency.
It significantly improves the secretion level of secreted proteins in cells and mice, reduces screening time, and achieves stable, controllable and accurate protein replacement therapy, suitable for inflammatory diseases, autoimmune diseases and cancer treatments, improving Treatment effect.
Smart Images

Figure BDA0005010456530000051 
Figure BDA0005010456530000052 
Figure BDA0005010456530000053
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a signal peptide mRNA for improving the expression level of secretory proteins and an mRNA engineering method and application thereof. Background Art
[0002] Messenger RNA (mRNA) is a single-stranded RNA transcribed from DNA. Its function is to carry genetic information and guide ribosomes to synthesize proteins. Due to its fast development speed, low immunogenicity, and no risk of gene integration, mRNA has developed into an emerging class of nucleic acid drugs. It is currently widely used in the research of preventive mRNA vaccines, tumor immunotherapy, protein replacement therapy, gene editing, and regenerative medicine. However, for therapeutic mRNA drugs, the protein expression level after mRNA translation is particularly important. At present, most studies are devoted to improving the delivery efficiency of mRNA delivery systems or delivering mRNA to specific organs, tissues or cells so that it can express proteins in cells and exert its efficacy. However, there are few studies on changing the signal peptide mRNA sequence in the mRNA sequence encoding secretory proteins through mRNA engineering technology to increase the secretion level of the target protein.
[0003] Signal peptides are short peptides located at the N-terminus of proteins, consisting of a short sequence of 15 to 30 amino acids. Their main function is to mediate the shuttling of proteins to organelles such as the nucleus and mitochondria, and to export proteins to the extracellular space through the secretory pathway. For mature secretory proteins, their signal peptides are usually removed before secretion outside the cell. Different types of secretory proteins often have very different expression and secretion efficiencies under the action of their respective signal peptides. For certain inflammatory diseases, autoimmune diseases, cancers, etc., therapeutic proteins are required to act extracellularly and maintain high levels in the circulatory system. At present, such diseases are usually treated with recombinant proteins, but recombinant proteins have a short half-life, complex large-scale production and purification processes, are difficult to control quality, and are expensive. Therefore, there is an urgent need to develop a stable, controllable, and accurate protein replacement therapy to achieve high-level expression of secretory proteins in the body.
[0004] In recent years, mRNA technology has developed rapidly and has shown broad application prospects in the fields of protein replacement therapy. After the exogenous mRNA obtained by in vitro transcription enters the cell with the help of delivery technology, it can be translated into the target protein in the cytoplasm without entering the cell nucleus, thus avoiding the risk of gene integration. However, the difference between mRNA drugs and protein drugs is that protein drugs are easily degraded after administration into the blood and have a short half-life, while mRNA drugs can be continuously translated into the target protein with the help of the protein translation system in the cytoplasm after being taken up by cells until the mRNA is finally degraded. The target protein can form intracellular proteins, membrane proteins, and secretory proteins that are secreted out of the cell according to the localization signal sequence. Therefore, the signal peptide mRNA sequence in the mRNA sequence encoding the secretory protein is transformed by mRNA engineering technology, which provides the possibility of achieving high levels of protein secretion. The present invention uses mRNA engineering transformation means to comprehensively screen and optimize the signal peptide in the in vitro transcribed mRNA sequence, improve the expression level of the secretory protein encoded by the mRNA, greatly reduce the time required for screening, and has broad application prospects. Summary of the invention
[0005] The main problem to be solved by the present invention is how to transform the signal peptide mRNA sequence in the mRNA sequence encoding the secretory protein by mRNA engineering technology to improve the expression level of the secretory protein encoded by the mRNA.
[0006] In order to solve the above problems, the present invention provides a nucleic acid molecule encoding a secretory protein, and the present invention also provides a generally applicable nucleic acid engineering technology.
[0007] The nucleic acid molecule encoding a secretory protein provided by the present invention comprises a signal peptide and the target protein. The nucleic acid sequence of the signal peptide replaces the nucleic acid sequence of the original signal peptide by mRNA engineering transformation technology to obtain the above-mentioned nucleic acid molecule encoding the secretory protein composed of the nucleic acid sequence of the signal peptide and the nucleic acid sequence of the original target protein. The nucleic acid sequence of the signal peptide is any one of the following:
[0008] 1) SEQ ID No. 25;
[0009] 2) SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ Any one of ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 or SEQ ID No. 30.
[0010] In the above nucleic acid molecule, the nucleic acid sequence of the signal peptide can significantly increase the secretion level of the secretory protein in cells and mice.
[0011] The secretory protein may be a secretory Gaussia luciferase protein (GLuc for short), a secretory human osteoprotegerin protein (OPG for short) or a secretory human vascular endothelial growth factor receptor 1 protein (sFlf-1 for short).
[0012] The mRNA corresponding to the secretory protein may be an mRNA encoding secretory GLuc (GLuc mRNA), an mRNA encoding secretory OPG (OPG mRNA), or an mRNA encoding secretory sFlt-1 (sFlt-1 mRNA).
[0013] Herein, the nucleic acid molecule encoding the secretory protein may be mRNA, and the mRNA comprises any one or a combination of at least two of a cap structure, a 5' untranslated region, a nucleic acid sequence encoding a signal peptide and the target protein, a 3' untranslated region, and a polyadenylic acid tail. The present invention takes GLuc mRNA, OPG mRNA, and sFlt-1 mRNA customized from Shanghai Weihuan Biotechnology Co., Ltd. (APExBIO) as an example.
[0014] The nucleic acid sequence of the target protein may be the mRNA sequence of the target protein.
[0015] In a specific embodiment, the nucleic acid molecule may be GLuc mRNA, which comprises a m7G (5') ppp (5') (2'OMeA) pG cap structure, a 5' untranslated region, a GLuc coding region (a nucleic acid sequence encoding a Gluc signal peptide and a Gluc target protein), a 3' untranslated region, and a polyadenylic acid tail of 120 adenylic acids. The nucleic acid sequence of the Gluc signal peptide is shown in SEQ ID No. 1-SEQ ID No. 30 (SEQ ID No. 1 is a nucleic acid sequence encoding the original Gluc signal peptide), and the corresponding GLuc mRNAs containing different nucleic acid sequences of the signal peptide are named GLuc mRNA1-GLucmRNA30.
[0016] In a specific embodiment, the nucleic acid molecule may be OPG mRNA, which comprises a m7G (5') ppp (5') (2'OMeA) pG cap structure, a 5' untranslated region, an OPG coding region (a nucleic acid sequence encoding an OPG signal peptide and the OPG target protein), a 3' untranslated region and a polyadenylic acid tail of 120 adenylic acids. The nucleic acid sequence of the OPG signal peptide is shown in SEQ ID No. 31 and SEQ ID No. 25, wherein SEQ ID No. 31 is a nucleic acid sequence encoding an OPG original signal peptide. The corresponding OPG mRNAs containing different nucleic acid sequences of the signal peptides are named OPG mRNA1 and OPG mRNA25, respectively.
[0017] In a specific embodiment, the nucleic acid molecule may be sFlt-1 mRNA, and the sFlt-1 mRNA comprises a m7G (5') ppp (5') (2'OMeA) pG cap structure, a 5' untranslated region, an sFlt-1 coding region (a nucleic acid sequence encoding a sFlt-1 signal peptide and the sFlt-1 target protein), a 3' untranslated region, and a polyadenylic acid tail of 120 adenylic acids. The nucleic acid sequence of the sFlt-1 signal peptide is shown in SEQ ID No. 32 and SEQ ID No. 25, wherein SEQ ID No. 32 is a nucleic acid sequence encoding the original signal peptide of sFlt-1. The corresponding sFlt-1 mRNAs containing different nucleic acid sequences of the signal peptide are named sFlt-1 mRNA1 and sFlt-1 mRNA25, respectively.
[0018] The present invention also provides the use of the following mRNA in improving the expression of a target protein, wherein the mRNA may be any of the following:
[0019] 1) SEQ ID No. 25;
[0020] 2) SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ Any one of ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 or SEQ ID No. 30.
[0021] The expression may be secretory expression.
[0022] The present invention also provides the use of the above mRNA in preparing a product for improving the expression of a target protein.
[0023] The present invention also provides the use of the mRNA in increasing the yield of target protein.
[0024] The present invention also provides the use of the mRNA in preparing a product for increasing the yield of a target protein.
[0025] The product may be a nucleic acid molecule (eg RNA).
[0026] The present invention also provides an mRNA engineering technology for modifying the signal peptide mRNA sequence in the mRNA sequence encoding the secretory protein, thereby improving the expression level of the secretory protein encoded by the mRNA. By replacing the nucleic acid sequence of the original signal peptide with the nucleic acid sequence of the signal peptide described above from different sources, the above-mentioned nucleic acid molecule encoding the secretory protein composed of the nucleic acid sequence of the signal peptide and the nucleic acid sequence of the target protein is obtained. The method can quickly improve the secretory expression level of the secretory protein encoded by the mRNA by screening the nucleic acid sequence of the signal peptide.
[0027] The present invention also provides a method for secretion of a nucleic acid molecule encoding a secretory protein into a eukaryotic host cell or a host animal, the method comprising introducing the nucleic acid molecule described above into a eukaryotic host cell or a host animal for expression, thereby increasing the secretion level of the target protein.
[0028] In the above application or method, the secretory protein is secreted Gaussia luciferase, secreted human osteoprotegerin or secreted human vascular endothelial growth factor receptor 1 protein.
[0029] The present invention also provides the use of the above-mentioned signal peptide in improving the secretory expression level of the target protein in a eukaryotic host cell.
[0030] The present invention also provides the use of the above-mentioned signal peptide in the preparation of a product for improving the secretory expression level of a target protein in a eukaryotic host cell.
[0031] Herein, the eukaryotic host cell may be HeLa cell, MC38 cell, MB49 cell, or 293T cell.
[0032] In the above method, the target protein may be Gaussia luciferase reporter protein or secretory human osteoprotegerin protein or secretory human vascular endothelial growth factor receptor 1 protein.
[0033] In the above method, the eukaryotic host animal may be a mouse.
[0034] The mouse may be a C57BL / 6 mouse.
[0035] In the above method, the method of introducing a nucleic acid molecule encoding a secretory protein into a eukaryotic host cell or a host animal for secretion comprises the step of mixing the nucleic acid molecule encoding a secretory protein as described above with a delivery vector.
[0036] The delivery vector can be commercial transfection reagents Lipofectamine 2000 and Lipofectamine MessengerMax.
[0037] The delivery carrier can also be the following organic phase: the main lipid molecule (9Z,9'Z,9"Z)-N,N',N"-[benzene-1,3,5-triyltri(methylene)]tri(9-octadecene-1-amine) (tB-UC18, dissolved in ethanol) with a concentration of 0.6 mg / mL and the auxiliary lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Sigma-Aldrich Trading Co., Ltd., Product No. 850725P) (dissolved in ethanol) with a concentration of 0.49 mg / mL are mixed in a volume ratio of 1:1 to obtain an organic phase.
[0038] The delivery vector may also be a mixed phase as follows: a main lipid molecule (9Z,9'Z,9"Z)-N,N',N"-[benzene-1,3,5-triyltri(methylene)]tri(dimethyl-9-octadecene-1-ammonium)iodide (qtB-UC18, dissolved in ethanol) with a concentration of 3 mg / mL is mixed evenly with 1.6 mg / mL DOPE (dissolved in ethanol) in a volume ratio of 1:1 to obtain an organic phase, and the organic phase and water are mixed evenly in a volume ratio of 1:9 to obtain a mixed phase.
[0039] The delivery carrier can also be the following organic phase: the main lipid molecule heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecanyloxy)hexyl)amino) caprylate (SM-102, Shanghai MacLean Biochemical Technology Co., Ltd., Catalog No. H960367) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Sigma-Aldrich Trading Co., Ltd., Catalog No. 850365P), cholesterol ((Sangon Biotechnology (Shanghai) Co., Ltd., Catalog No. A100433), polyethylene glycol lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 (DMG-PEG2000, TargetMol, Catalog No. T9098) are dissolved in ethanol at a molar ratio of 50:10:38.5:1.5, and then a 50 mM citrate buffer solution (pH 5.0) is added at a volume ratio (ethanol: citrate buffer solution) of 9:1. 3), mix well to obtain an organic phase.
[0040] Herein, the delivery vehicle is a lipid nanoparticle composed of a main lipid molecule and an auxiliary lipid molecule; the main lipid molecule is as follows:
[0041] 1) The main lipid molecule is tB-UC18, with the molecular formula C 63 H 117 N3, the structural formula of tB-UC18 is as follows:
[0042]
[0043] 2) The main lipid molecule is qtB-UC18, with a molecular formula of C 69 H 132 I3N3, the structural formula of qtB-UC18 is as follows:
[0044]
[0045] 3) The main lipid molecule is TT3, with the molecular formula C 90 H 174 N6O3, the structural formula of TT3 is as follows:
[0046]
[0047] 4) The main lipid molecule is SM-102, with a molecular formula of C 44 H 87 NO5, the structural formula of SM-102 is as follows
[0048]
[0049] As shown:
[0050] (Formula 4);
[0051] 5) The auxiliary lipid molecule is selected from at least one of the following: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and polyethylene glycol lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 (DMG-PEG2000).
[0052] In the delivery vector, the molar ratio of the main lipid molecule tB-UC18 to the auxiliary lipid molecule DOPE is 1:1, and the molar ratio of the N atom of tB-UC18 to the P atom in the mRNA is 60:40;
[0053] In the delivery vector, the molar ratio of the main lipid molecule qtB-UC18 to the auxiliary lipid molecule DOPE is 1:1, and the molar ratio of the N atom of qtB-UC18 to the P atom in the mRNA is 60:40;
[0054] In the delivery vector, the main lipid molecule TT3 and the auxiliary lipid molecules DOPE, cholesterol, and DMG-PEG2000 are calculated in molar proportions of 22:33.1:44.1:0.8, and the mass ratio of TT3 to mRNA is 10:1;
[0055] In the delivery vector, the main lipid molecule SM-102 and the auxiliary lipid molecules DSPC, cholesterol, and DMG-PEG2000 are calculated in molar proportions of 50:10:38.5:1.5, and the mass ratio of SM-102 to mRNA is 10.75:1.
[0056] The present invention also provides a method for preparing the lipid nanoparticles described above, comprising: mixing an mRNA solution with the delivery carrier to obtain the mRNA lipid nanoparticles.
[0057] In a specific embodiment, the preparation method specifically comprises: mixing the main lipid molecule, the auxiliary lipid molecule and an organic solvent to obtain an organic phase containing a delivery vector; mixing the organic phase with an mRNA solution to obtain the mRNA lipid nanoparticles encapsulating the secretory protein. The solvent of the mRNA solution is a buffer solution. The pH value of the buffer solution is 3-8. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 The present invention is an agarose nucleic acid electrophoresis diagram of mRNA encoding wild-type Gaussia luciferase reporter protein containing signal peptide nucleic acid sequences of SEQ ID No.1 to SEQ ID No.30 (named GLuc mRNA1 to GLuc mRNA30), mRNA encoding wild-type secretory human osteoprotegerin containing signal peptide nucleic acid sequence of SEQ ID No.31 (named OPG mRNA1), and mRNA encoding engineered secretory human osteoprotegerin containing signal peptide nucleic acid sequence of SEQ ID No.25 (named OPG mRNA25), as well as mRNA encoding wild-type secretory human vascular endothelial growth factor receptor 1 containing signal peptide nucleic acid sequence of SEQ ID No.32 (named sFlt-1 mRNA1), and mRNA encoding engineered secretory human osteoprotegerin containing signal peptide nucleic acid sequence of SEQ ID No.25 (named sFlt-1 mRNA25).
[0059] Figure 2 The commercial Lipofectamine 2000 reagent was used to deliver GLuc mRNA containing different signal peptide mRNA sequences to 293T cells expressing Gaussia luciferase.
[0060] Figure 3 Commercial Lipofectamine 2000 reagent was used to deliver GLuc mRNA1, GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 containing different signal peptide sequences to HeLa cells ( Figure 3 Middle (a)), MC38 cells ( Figure 3 Middle (b)), MB49 cells ( Figure 3 Gaussia luciferase expression in (c).
[0061] Figure 4 To commercialize Lipofectamine MessengerMAX( Figure 4 Middle (a)), tB-UC18 ( Figure 4 Middle (b)), qtB-UC18 ( Figure 4Middle (c)) Transfection reagents delivered GLuc mRNA1, GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 containing different signal peptide sequences to 293T cells for Gaussia luciferase expression.
[0062] Figure 5 Commercial Lipofectamine 2000 reagent was used to deliver GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 to 293T cells for Gaussia luciferase expression at different time points.
[0063] Figure 6 The commercial Lipofectamine 2000 reagent was used to deliver different doses of GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 to Gaussia luciferase expression in 293T cells.
[0064] Figure 7 Gaussia luciferase expression 3 h after SM-102 lipid nanoparticles loaded with GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 (dose converted to mRNA is 0.25 mg / kg) were injected into C57BL / 6 mice via the tail vein.
[0065] Figure 8 The relative OPG expression of 200 ng of OPG mRNA1 and OPG mRNA25 was delivered to 293T cells using the commercial Lipofectamine MessengerMAX reagent.
[0066] Fig. 9 Relative OPG expression 1h, 4h, and 8h after SM-102 lipid nanoparticles loaded with OPG mRNA1 and OPG mRNA25 (dose converted to mRNA is 0.5 mg / kg) were injected into C57BL / 6 mice via the tail vein.
[0067] Fig.10 Relative OPG expression 4 hours after TT3 lipid nanoparticles loaded with OPG mRNA1 and OPG mRNA25 (dose converted to mRNA is 0.5 mg / kg) were injected into C57BL / 6 mice via the tail vein.
[0068] Fig.11 The relative sFlt-1 expression of 200 ng of sFlt-1 mRNA1 and sFlt-1 mRNA25 was delivered to 293T cells using the commercial Lipofectamine MessengerMAX reagent.
[0069] Fig.12Relative sFlt-1 expression 4 hours after SM-102 lipid nanoparticles (a) and TT3 lipid nanoparticles (b) loaded with sFlt-1 mRNA1 and sFlt-1 mRNA25 (the dose converted to mRNA is 0.5 mg / kg) were injected into C57BL / 6 mice via the tail vein.
[0070] * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, NS indicates p > 0.05, and # indicates below the detection limit. DETAILED DESCRIPTION
[0071] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0072] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0073] Unless otherwise specified, the quantitative tests in the following examples were performed three times and the results were averaged.
[0074] The tB-UC18 in the following examples has been described in: Li M, Li S, Huang Y, et al. Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies. Adv Mater. 2021; 33(34): e2101707. doi: 10.1002 / adma.202101707. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0075] The qtB-UC18 in the following examples has been described in: Huang Y, Wu J, Li S, et al. Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies. Theranostics. 2024; 14(2): 830-842. Published 2024 Jan 1. doi: 10.7150 / thno.90071. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0076] TT3 in the following embodiments has been described in: Li B, Luo X, Deng B, et al. An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. NanoLett. 2015; 15(12): 8099-8107. doi: 10.1021 / acs.nanolett.5b03528. and Zeng C, Hou X, Yan J, et al. Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo. Adv Mater. 2020; 32(40): e2004452. doi: 10.1002 / adma.202004452. The public can obtain the biological material from the applicant, which is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0077] SM-102 in the following embodiments has been recorded in: Suzuki Y, Ishihara H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metab Pharmacokinet. 2021; 41: 100424. doi: 10.1016 / j.dmpk.2021.100424 and Han X, Alameh MG, Gong N, et al. Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. Nat Chem. Published online July 9, 2024. doi: 10.1038 / s41557-024-01557-2. The public can obtain the biological material from the applicant, which is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0078] The following examples used Graphpad prism8 statistical software to process the data, and the experimental results were expressed as mean ± standard error, and the unpaired t test (two tailed) was used for inspection. (*) indicates P < 0.05, (**) indicates P < 0.01, (***) indicates P < 0.001, and NS indicates p > 0.05.
[0079] Example 1. Engineering modification and purity identification of mRNA
[0080] The names of the mRNAs in this example are GLuc mRNA1-GLuc mRNA30, all of which contain a m7G(5')ppp(5')(2'OMeA)pG cap structure, a 5' untranslated region, a GLuc coding region (nucleic acid sequences encoding different GLuc signal peptides and nucleic acid sequences encoding Gluc target proteins), a 3' untranslated region and a poly(A) tail of 120 adenylic acids.
[0081] The nucleic acid sequences encoding different GLuc signal peptides of the above mRNA1-GLuc mRNA30 are shown in SEQ ID No.1-SEQ ID No.30 (wherein SEQ ID No.1 is the nucleic acid sequence encoding the original signal peptide of Gluc, and SEQ ID No.2-SEQ IDNo.30 is the nucleic acid sequence encoding the signal peptide after Gluc engineering modification), and the corresponding GLuc mRNAs containing different nucleic acid sequences of the signal peptides are named GLuc mRNA1-GLuc mRNA30. The above mRNAs were custom synthesized by APExBIO of Shanghai Weihuan Biotechnology Co., Ltd.
[0082] The nucleotide sequence of the GLuc mRNA1 coding region is SEQ ID No. 33, wherein nucleotides 1 to 3 of SEQ ID No. 33 are the start codon, nucleotides 1 to 51 (SEQ ID No. 1) encode the GLuc original signal peptide, nucleotides 52 to 555 encode the Gluc target protein, and nucleotides 556 to 561 are two consecutive stop codons.
[0083] The difference between GLuc mRNA2-GLuc mRNA30 and GLuc mRNA1 is only the nucleotide sequence of the coding region. The nucleotide sequence of the coding region of GLuc mRNA2-GLuc mRNA30 is different from the nucleotide sequence of the coding region of GLuc mRNA1 only in that the nucleotide sequence of SEQ ID No.1 is replaced by any nucleotide sequence of SEQ ID No.2-SEQ ID No.30, and the other structures are the same.
[0084] In SEQ ID No. 1 to SEQ ID No. 30, T refers to uracil nucleotide (U).
[0085] The nucleotide sequence of the OPG mRNA1 coding region is SEQ ID No.34, wherein nucleotides 1-3 of SEQ ID No.34 are the start codon, nucleotides 1-63 (SEQ ID No.31) encode the OPG original signal peptide, nucleotides 64-1203 encode the OPG target protein, and nucleotides 1204-1206 are the stop codons.
[0086] The only difference between OPG mRNA25 and OPG mRNA1 is the nucleotide sequence of the coding region. The only difference between the nucleotide sequence of the coding region of OPG mRNA25 and the nucleotide sequence of the coding region of OPG mRNA1 is that the nucleotide sequence of SEQ ID No.31 is replaced by the nucleotide sequence of SEQ ID No.25, and the other structures are the same.
[0087] The nucleotide sequence of the sFlt-1mRNA1 coding region is SEQ ID No.35, wherein the nucleotides 1-3 of SEQ ID No.35 are the start codon, the nucleotides 1-78 (SEQ ID No.32) encode the sFlt-1 original signal peptide, the nucleotides 79-2061 encode the sFlt-1 target protein, and the nucleotides 2062-2064 are the stop codons.
[0088] The only difference between sFlt-1mRNA25 and sFlt-1mRNA1 is the nucleotide sequence of the coding region. The only difference between the nucleotide sequence of the coding region of sFlt-1mRNA25 and the nucleotide sequence of the coding region of sFlt-1mRNA1 is that the nucleotide sequence of SEQ ID No.32 is replaced by the nucleotide sequence of SEQ ID No.25, and the other structures are the same.
[0089] Purity and integrity test of GLuc mRNA1-GLuc mRNA30, OPG mRNA25 and OPG mRNA1, sFlt-1 mRNA25 and sFlt-1 mRNA1: Take the above mRNAs and add them to 1.5% non-denaturing TAE agarose gel for electrophoresis identification. The electrophoresis results are as follows Figure 1 As shown, the obtained band is single, indicating that the mRNA is of high purity and has no obvious degradation.
[0090] Example 2: Study on the expression level of Gaussia luciferase encoded by GLuc mRNA1-GLuc mRNA30 in 293T cells
[0091] 293T cells (Biyuntian, C6008) were plated in 96-well plates at 20,000 cells / well and cultured in a CO2 incubator for 24 hours until the cells adhered to the wall. 0.2 μL of commercial transfection reagent Lipofectamine 2000 (Thermo Fisher, 11668030) was incubated with 200 ng of any of the 30 engineered mRNAs GLuc mRNA1-GLuc mRNA30 for 10 minutes and added to each well. After 24 hours, the cell culture plate was taken out and equilibrated at room temperature for 10 minutes, and then Gaussia luciferase activity was detected using the Gaussia luciferase reporter gene detection kit (Biyuntian, RG072M).
[0092] Specific detection process: Before the detection, restore the Gaussian substrate buffer to room temperature, take 6mL of Gaussian luciferase detection buffer, add 60μL of Gaussian luciferase detection substrate (100×) and mix thoroughly to obtain Gaussian luciferase detection working solution. Add 95μL of the freshly prepared Gaussian luciferase detection working solution to each well, shake at room temperature for 2 minutes on a shaker (75rpm), then let it stand for 3 minutes, and use an enzyme reader to detect the bioluminescence value. The high or low value of the luminescence signal represents the protein secretion level of mRNA translation.
[0093] Test results such as Figure 2 As shown, compared with GLuc mRNA1 containing SEQ ID No.1, GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 containing SEQ ID No.4, SEQ ID No.22, and SEQ ID No.25 showed protein secretion levels comparable to or higher than that of GLuc mRNA1 in 293T cells.
[0094] Example 3. Expression levels of Gaussia luciferase encoded by GLuc mRNA25, GLuc mRNA4 and GLuc mRNA22 in different cells
[0095] The only difference between Example 3 and Example 2 is that the tested mRNAs are GLuc mRNA1, GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25; the tested cells are Hela cells (10,000 cells / well; Bio-Tech, C6330), MC38 cells (20,000 cells / well; Bio-Tech, C7399), and MB49 cells (40,000 cells / well; Hunan Fenghui Biotechnology Co., Ltd., CL0202); and the other test conditions are the same.
[0096] Figure 3 The experimental results in (a)-(c) show that different mRNAs have different protein secretion levels in different cells. GLuc mRNA25 showed a secretion level comparable to that of the original sequence GLuc mRNA1 in Hela cells, while in MC38 cells and MB49 cells, GLuc mRNA22 and GLuc mRNA25 both showed higher protein secretion levels than the control GLuc mRNA1.
[0097] Example 4 Effects of different delivery vectors on the expression levels of GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 Gaussia luciferase
[0098] The only difference between Example 4 and Example 2 is that the tested mRNAs are GLuc mRNA1, GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25; the delivery vectors used are Lipofectamine MessengerMax, tB-UC18 nanoparticles, and qtB-UC18 nanoparticles; and the other test conditions are the same.
[0099] The specific preparation methods of the delivery vectors are as follows:
[0100] 1. 0.2 μL of commercial transfection reagent Lipofectamine MessengerMax (Thermo Fisher, LMRNA001) was incubated with 200 ng of GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 for 10 min, and then added to each well.
[0101] 2. The main lipid molecule (9Z,9'Z,9"Z)-N,N',N"-[benzene-1,3,5-triyltri(methylene)]tri(9-octadecene-1-amine) (tB-UC18, dissolved in ethanol) with a concentration of 0.6 mg / mL and the auxiliary lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Sigma-Aldrich Trading Co., Ltd., Catalog No. 850725P) (dissolved in ethanol) with a concentration of 0.49 mg / mL were mixed in a volume ratio of 1:1 to obtain an organic phase; the organic phase was incubated with 200 ng of GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 at a volume ratio of 1:9 for 10 minutes and added to each well.
[0102] The synthesis route of the above-mentioned main lipid molecule tB-UC18 can be: add benzene trimesic acid and 9-octadecene-1-amine in a molar equivalent of 1:3.6 to an ethanol / dichloromethane solution. After the raw material is completely dissolved, add anhydrous sodium sulfate (2mmol), stir at 35°C for 24h, remove Na2SO4, and rotary evaporate the solvent to obtain a Schiff base intermediate. The intermediate product is dissolved in ethanol / dichloromethane, 3mmol sodium borohydride is added, and stirred at room temperature for 24h. After rotary evaporation to remove the solvent, add an aqueous solution of ammonium bicarbonate and extract three times with chloroform. After the organic phase is separated and washed with water, the solvent is removed, and the resulting product is separated and purified using a rapid purification preparative chromatograph to obtain the main lipid molecule tB-UC18.
[0103] 3. The main lipid molecule (9Z,9'Z,9"Z)-N,N',N"-[benzene-1,3,5-triyltri(methylene)]tri(dimethyl 9-octadecene-1-ammonium)iodide (qtB-UC18, dissolved in ethanol) with a concentration of 3 mg / mL was mixed with 1.6 mg / mL DOPE (dissolved in ethanol) at a volume ratio of 1:1 to obtain an organic phase. The organic phase was mixed with water at a volume ratio of 1:9 to obtain a mixed phase; the mixed phase was incubated with 200 ng of GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 at a volume ratio of 3:7 for 10 minutes and added to each well.
[0104] The synthesis route of the above-mentioned main lipid molecule qtB-UC18 can be: tB-UC18, potassium iodide and potassium carbonate are added to an ethanol solution in a molar equivalent of 1:21:4.5, stirred at 40°C for 72 hours, water is added and extracted with dichloromethane three times, anhydrous sodium sulfate is added, and then filtered and rotary evaporated to obtain the main lipid molecule qtB-UC18.
[0105] The results are as follows Figure 4 As shown in (a)-(c), when GLuc mRNA4, GLuc mRNA22, and GLuc mRNA25 were delivered using different vectors, GLuc mRNA25 showed a higher protein secretion level than the original sequence GLuc mRNA1.
[0106] Example 5. Expression levels of Gaussia luciferase encoded by GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 in 293T cells at different time points.
[0107] The only difference between Example 5 and Example 2 is that the tested mRNAs are GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25; the testing time is 6, 12, 24, and 48 hours; and the other testing conditions are the same.
[0108] The results are as follows Figure 5 As shown, the Gaussia luciferase expression levels of GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 in 293T cells were highest at 24 h.
[0109] Example 6. Expression levels of Gaussia luciferase encoded by GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 at different treatment doses in 293T cells
[0110] The only difference between Example 6 and Example 2 is that the test mRNA is GLuc mRNA1, GLuc mRNA22, and GLucmRNA25; the test dose is 0.05 μL, 0.1 μL, 0.2 μL, and 0.4 μL of the commercial transfection reagent Lipofectamine 2000 and 50 ng, 100 ng, 200 ng, and 400 ng mRNA, respectively, incubated for 10 min, and then added to each well; the other test conditions are the same.
[0111] The results are as follows Figure 6 As shown, within the tested range, the luciferase expression levels of GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 in 293T cells increased with increasing mRNA doses.
[0112] Example 7. Expression levels of Gaussia luciferase encoded by GLuc mRNA1 and GLuc mRNA25 in C57BL / 6 mice
[0113] The main lipid molecule heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)caprylate (SM-102, Shanghai MacLean Biochemical Technology Co., Ltd., Catalog No. H960367) and the auxiliary lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Sigma-Aldrich Trading Co., Ltd., Catalog No. 850365P), cholesterol ((Sangon Biotechnology (Shanghai) Co., Ltd., Catalog No. A100433), polyethylene glycol lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 (DMG-PEG2000, TargetMol, Catalog No. T9098) were dissolved in ethanol at a molar ratio of 50:10:38.5:1.5, respectively, and then 50 mM citrate buffer solution (pH 3) was added at a volume ratio (ethanol: citrate buffer solution) of 9:1, and mixed evenly to obtain an organic phase.
[0114] GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25 were diluted with 50 mM citrate buffer solution (pH 3) to obtain mRNA working solution.
[0115] According to the final mass ratio of SM-102 to mRNA set to 10.75:1, the organic phase and mRNA working solution were mixed in equal volumes, and then quickly pipetted to mix to obtain a mixed phase. The mixed phase was then mixed with an equal volume of PBS buffer solution (1×, pH 7.4), gently pipetted to mix, and allowed to stand at room temperature for 10 minutes to obtain an mRNA delivery vector (referred to as SM-102 lipid nanoparticles).
[0116] The prepared mRNA lipid nanoparticles were immersed in a PBS buffer solution (pH 7.4) using a dialysis cup with a molecular weight cutoff of 3.5K MWCO (ThermoFisher, catalog number 88400) and dialyzed at room temperature for 30 min on a shaker (100 rpm).
[0117] Female C57BL / 6J mice (Zhuhai Baishitong Biotechnology Co., Ltd.) aged about 7 weeks were used as experimental subjects, and the mRNA lipid nanoparticles prepared in the above step were injected into the mice through the tail vein at a dosage of 0.25 mg / kg, encapsulating GLuc mRNA1, GLuc mRNA22, and GLuc mRNA25.
[0118] 3 hours after administration, the blood of mice was collected and placed in an anticoagulant tube containing EDTA-K2. Half an hour after blood collection, the blood was centrifuged in a built-in centrifuge (4°C, 1000rcf) for 10 minutes and the supernatant was taken to obtain mouse plasma.
[0119] 50 μL of mouse plasma obtained by the above treatment was used for detection. The specific detection steps were the same as those in Example 2.
[0120] The results are as follows Figure 7 As shown, compared with GLuc mRNA1, GLuc mRNA25 can significantly enhance the secretion ability of the reporter protein in mice, and its secretion level is 3 times that of GLuc mRNA1.
[0121] Example 8. Expression levels of OPG encoded by OPG mRNA1 and OPG mRNA25 in 293T cells
[0122] The only difference between Example 8 and Example 2 is that the tested mRNAs are OPG mRNA1 and OPG mRNA25; the commercial transfection reagent used is Lipofectamine MessengerMax (Thermo Fisher, LMRNA001). 24 hours after administration, the cell culture supernatant was taken out, and then the protein expression amount (protein content in the supernatant) in the supernatant was detected using a human osteoprotegerin (OPG) enzyme-linked immunosorbent assay kit (Elabscience, E-EL-H1341).
[0123] The results are as follows Figure 8 As shown, compared with OPG mRNA1 containing SEQ ID No.31, OPG mRNA25 can significantly improve the secretion ability of OPG in 293T cells, and its secretion level is 1.2 times that before optimization.
[0124] Example 9. Expression levels of OPG encoded by OPG mRNA1 and OPG mRNA25 in C57BL / 6 mice at different time points
[0125] The difference between Example 9 and Example 7 is that the mRNA tested is OPG mRNA1 and OPG mRNA25, and the dosage is 0.5 mg / kg; plasma is collected 1h, 4h, and 8h after administration, and the protein expression in plasma is detected using a human osteoprotegerin (OPG) enzyme-linked immunosorbent assay kit (Elabscience, E-EL-H1341).
[0126] The results are as follows Fig. 9 As shown, OPG mRNA25 can increase the secretion capacity of human osteoprotegerin protein in mice at 1h, 4h, and 8h after administration, and reaches the highest level 4h after administration.
[0127] Example 10. Expression levels of OPG encoded by OPG mRNA1 and OPG mRNA25 in C57BL / 6 mice
[0128] The difference between Example 10 and Example 7 is that the tested mRNAs are OPG mRNA1 and OPG mRNA25, and the dosage is 0.5 mg / kg. The mRNA delivery carrier used is TT3 lipid nanoparticles; 4 hours after administration, the protein expression in plasma is detected using a human osteoprotegerin (OPG) enzyme-linked immunosorbent assay kit (Elabscience, E-EL-H1341).
[0129] The difference between the preparation method of TT3 lipid nanoparticles and the preparation method of SM-102 lipid nanoparticles is that the main lipid molecule used is 1,3,5-tris(N1,N3,N5-(3-didodecylaminopropyl))benzamide (TT3), the auxiliary lipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Sigma-Aldrich Trading Co., Ltd., Catalog No. 850725P), the molar ratio of the organic phase components is 20:30:40:0.75, and the final mass ratio of TT3 to mRNA is set to 10:1.
[0130] The synthetic route of the above main lipid molecule TT3 can be: under ice bath conditions, 1,3,5-benzenetricarboxylic acid chloride and N-tert-butyloxycarbonyl-1,3-propylenediamine are added to a dichloromethane solution at a molar equivalent of 1:4, stirred at room temperature overnight, dichloromethane and ultrapure water are added to extract the organic phase, anhydrous sodium sulfate is added to the organic phase for drying, and the product is purified using a rapid silica gel chromatography system. The purified product and trifluoroacetic acid are added to a dichloromethane solution at a molar equivalent of 1.1, stirred at room temperature for 1 hour, and the solvent is removed. The obtained product and triethylamine are added to a 10mL anhydrous tetrahydrofuran solution at a molar equivalent of 1:4, stirred at room temperature for 0.5h, and then dodecanal (9 molar equivalents) and sodium triacetoxyborohydride (20 molar equivalents) are added dropwise to the reaction, and stirred at room temperature for 48h. After the organic phase is separated and washed with water, the solvent is removed and the obtained product is separated and purified using a rapid purification preparative chromatograph to obtain the main lipid molecule 1,3,5-tris(N1,N3,N5-(3-didodecylaminopropyl))benzamide (TT3).
[0131] The results are as follows Fig.10 As shown, compared with OPG mRNA1 containing SEQ ID No.31, OPG mRNA25 can significantly improve the secretion capacity of OPG in mice, and its secretion level is 1.5 times that before optimization.
[0132] Example 11. Expression Levels of sFlt-1 Encoded by sFlt-1 mRNA1 and sFlt-1 mRNA25 in 293T Cells
[0133] The only difference between Example 11 and Example 2 is that the tested mRNAs are sFlt-1mRNA1 and sFlt-1mRNA25; the commercial transfection reagent used is Lipofectamine MessengerMax (Thermo Fisher, LMRNA001). 24 hours after administration, the cell culture supernatant was taken out, and then the protein expression amount (protein content in the supernatant) in the supernatant was detected using a human vascular endothelial growth factor receptor 1 enzyme-linked immunosorbent assay kit (Elabscience, E-EL-H6175).
[0134] The results are as follows Fig.11 As shown, compared with sFlt-1mRNA1 containing SEQ ID No.32, sFlt-1mRNA25 can significantly improve the secretion ability of sFlt-1 in 293T cells, and its secretion level is 2.2 times that before optimization.
[0135] Example 12. Expression Levels of sFlt-1 Encoded by sFlt-1mRNA1 and sFlt-1mRNA25 in C57BL / 6 Mice
[0136] The difference between Example 12 and Example 11 is that the mRNA tested is sFlt-1mRNA1 and sFlt-1mRNA25; the mRNA delivery vectors used include SM-102 lipid nanoparticles and TT3 lipid nanoparticles (the preparation method of TT3 lipid nanoparticles is the same as that of Example 10), and 4 hours after administration, the protein expression in plasma is detected using a human vascular endothelial growth factor receptor 1 enzyme-linked immunosorbent assay kit (Elabscience, E-EL-H6175).
[0137] The results are as follows Fig.12 As shown in (a) and (b), compared with sFlt-1mRNA1 containing SEQ ID No.32, using different lipid nanoparticles to deliver sFlt-1mRNA25 can significantly improve the secretion capacity of sFlt-1 in mice, and the secretion levels are 4 times higher than those before optimization ( Fig.12 a) and 2.6 times ( Fig.12 (b)
[0138] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. A nucleic acid molecule encoding a secretory protein, characterized in that The secretory protein comprises a signal peptide and a target protein from the N-terminus to the C-terminus, the nucleic acid molecule is mRNA, and the mRNA of the signal peptide is any one of the following: 1) SEQ ID No. 25; 2) SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ Any one of ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 or SEQ ID No.
30.
2. The nucleic acid molecule according to claim 1, characterized in that The nucleic acid molecule is mRNA, and the nucleic acid molecule contains a cap structure, a 5'UTR, the mRNA of the signal peptide, the mRNA of the target protein, a 3'UTR and a PolyA tail.
3. The use of mRNA in improving the expression of target protein, characterized in that: The mRNA is any of the following: 1) SEQ ID No. 25; 2) SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ Any one of ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 or SEQ ID No.
30.
4. The use of mRNA in preparing a product for improving the expression of a target protein, characterized in that: The mRNA is any of the following: 1) SEQ ID No. 25; Any one of SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ ID No.17, SEQ ID No.18, SEQ ID No.19, SEQ ID No.20, SEQ ID No.21, SEQ ID No.22, SEQ ID No.23, SEQ ID No.24, SEQ ID No.26, SEQ ID No.27, SEQ ID No.28, SEQ ID No.29 or SEQ ID No.
30.
5. The use of mRNA in increasing the yield of target protein, characterized in that: The mRNA is any one of the following: 1) SEQ ID No.25; 2) Any one of SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ ID No.17, SEQ ID No.18, SEQ ID No.19, SEQ ID No.20, SEQ ID No.21, SEQ ID No.22, SEQ ID No.23, SEQ ID No.24, SEQ ID No.26, SEQ ID No.27, SEQ ID No.28, SEQ ID No.29 or SEQ ID No.
30.
6. The use of mRNA in preparing a product for increasing the yield of a target protein, characterized in that: The mRNA is any one of the following: 1) SEQ ID No.25; 2) SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.9, SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, SEQ ID No.14, SEQ ID No.15, SEQ ID No.16, SEQ Any of ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29 or SEQ ID No.
30.
7. A method for increasing the secretion of a target protein in a eukaryotic host cell, characterized in that: The method comprises introducing the nucleic acid molecule of claim 1 or 2 into a eukaryotic host cell for expression, thereby increasing the secretion level of the target protein.
8. An mRNA engineering technology for increasing secretion of a target protein from a eukaryotic host cell, characterized in that: The technology comprises replacing the original signal peptide nucleic acid sequence with the signal peptide nucleic acid sequence from different sources to obtain the above-mentioned nucleic acid molecule encoding the secretory protein composed of the signal peptide nucleic acid sequence and the target protein nucleic acid sequence.
9. Use of the signal peptide according to claim 1 or 2 in improving the secretory expression level of a target protein in a eukaryotic host cell.
10. Use of the signal peptide according to claim 1 or 2 in the preparation of a product for improving the secretory expression level of a target protein in a eukaryotic host cell.
Citation Information
Cited By
NPL three-modification tag and application thereof in improving exosome secretion level of target protein
CN121574194A
